Molecular risk stratification in normal-karyotype acute myeloid leukemia (AML) uses the co-occurrence pattern of recurrent gene mutations to refine prognosis beyond single-mutation classification schemes, reflecting the principle that combinations of mutations can have interactive (additive or competing) effects on survival rather than each mutation acting independently. This belongs to the domain of molecular hematologic oncology and genomic risk classification, relating to the broader discipline of precision medicine, where multi-gene mutation profiles inform treatment decisions such as eligibility for hematopoietic stem cell transplantation.
Molecular risk stratification in normal-karyotype acute myeloid leukemia (AML) uses the co-occurrence pattern of recurrent gene mutations to refine prognosis beyond single-mutation classification sch…